Cardiovascular data presented for obesity candidates Qnexa (phentermine/topiramate) and Contrave (naltrexone/bupropion) at the American College of Cardiology (ACC) meeting in New Orleans might have boosted shares of Vivus Inc. and Orexigen Therapeutics Inc. Monday, but those results are unlikely to ease the path to approval for either drug.